首頁 > 市場調查報告書 > 製藥

癌症呼吸器

市場調查報告書

商品編碼

1140730

全球鼻咽癌市場-2022-2029

Global Nasopharyngeal Cancer Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

提高對鼻咽癌的認識是市場增長的驅動力

對鼻咽癌診治的認識不斷提高。過去，由於政府力度不夠，發病率相對較低，鼻咽癌在公眾中並不為人所知，現在正在上升。因此，我們在多個基層醫療保健中心開展了提高對鼻咽癌認識的活動，針對易患鼻咽癌的人群。因此，鼻咽癌診斷和治療的日益普及正在推動全球鼻咽癌市場的增長。

然而，鼻咽癌的高昂治療費用對市場增長產生了負面影響。化療、手術和放療等高昂的治療費用在沒有保險的癌症患者中造成了自付費用。不斷上漲的藥品價格增加了治療的整體經濟負擔。這可能是全球鼻咽癌治療市場的障礙。鼻咽癌市場有很多優勢，也有很多劣勢。高昂的治療成本和副作用是鼻咽癌市場的障礙。

地理滲透

亞太地區將是預測期內的主要地區。

該研究按地區分析了全球市場的動物幹細胞治療市場，包括北美、歐洲、亞太地區、南美、中東和非洲。

預計亞太地區將在預測期內增長最快。鼻咽癌是亞太地區最常見的頭頸部癌症之一。據說雄性比雌性更容易繁殖兩到三倍。發病高峰在 50 至 60 歲之間。這種癌症常見於東南亞。此外，世界上鼻咽癌發病率最高的五個國家分別是印度尼西亞、中國、越南、印度和馬來西亞。根據美國癌症協會發表的一項研究，中國部分地區每 10 萬男性中高達 25-30 例，每 10 萬女性中高達 15-20 例。由於鼻咽癌治療和程序的便利性和可用性，發達地區對鼻咽癌市場的需求正在增加。公司正在大力投資發展中地區，以提供有效的治療解決方案，以實現更高質量的護理、更高的效率和更好的患者治療效果。此外，發展中地區對醫療保健意識的提高以及對 IT 和醫療保健技術的支出增加也有望推動鼻咽癌市場對有效治療的總體需求。

競爭格局

由於主要競爭者的存在，鼻咽癌市場是一個競爭激烈的市場。市場上的一些主要關鍵參與者是 Bristol-Myers Squibb、Cyclacel Pharmaceuticals Inc.、Eli Lilly & Co.、GLAXOSMITHKLINE PLC、Merck & Co.、Novartis International AG、Ono Pharmaceutical Co., Ltd.、Safoni、Theravectysys、Merck &Co。 Safoni、Theravectis SA 等主要參與者正在為全球鼻咽癌市場的增長採用新產品發布或擴展策略。 2022 年 3 月，百時美施貴寶以每股 76 美元的價格收購了領先的精準腫瘤學公司 TurningPoint Therapeutics。此次收購將通過增加一流的晚期精準腫瘤學資產，幫助擴大公司領先的腫瘤學專營權。 2021 年 7 月，禮來公司宣布將以 10 億美元收購推動 1 型糖尿病 (TD1) 治療的私營生物技術公司 Promoter Technologies。此次收購將加速 T1D 患者的下一代、改變生活的治療。 2021年4月，專注於罕見癌症靶向治療的加州生物製藥公司GLAXOSMITHKLINE PLC收購了Sierra Oncology；被收購。此次收購還包括莫莫替尼，這是一種具有獨特雙重作用機制的晚期候選藥物，可以解決貧血性骨髓纖維化患者未滿足的醫療需求。此次收購將有助於擴大我們創新的腫瘤學產品組合。

COVID-19 的影響將對全球鼻咽癌市場產生負面影響。

由於大流行期間醫院就診率和診斷率降低，COVID-19 大流行阻礙了鼻咽癌市場的增長。臨床數據顯示，癌症患者（其中許多是老年人和免疫抑制患者）更容易感染 COVID-19。在 COVID-19 大流行期間，在家中保持安全和增強免疫力已成為主要問題，導致 2020 年就診次數減少和鼻咽癌市場低迷。

全球鼻咽癌市場報告提供大約 50 個市場數據表、42 個圖表和 170 頁內容

Market Overview

Nasopharyngeal Cancer Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 4.7 % during the forecast period (2022-2029).

Nasopharyngeal cancer is a rare therapy of malignant cancer that appears in the nasopharynx. It is the upper part of the throat behind the nose. The nasopharynx is situated at the base of the skull, directly above the roof of the mouth. Nasopharyngeal cancer generally starts in the squamous cells that track the nasopharynx. The exact sources of nasopharyngeal cancer are unknown; however, a few risk factors are linked with nasopharyngeal cancer. Exposure to the Epstein-Barr virus is deemed a common risk factor for nasopharyngeal cancer. Also, people of East Asian or Chinese ancestry are more prone to cancer. Early symptoms of nasopharyngeal cancer involve a sore throat, lump in the nose or neck, difficulty in breathing or speaking, difficulty in hearing, pain or ringing in the ear or headaches. The nasopharyngeal cancer market has grown significantly at a strong CAGR due to the increasing patient count with nasopharyngeal cancer. The nasopharyngeal cancer market will likely grow globally with technological advancement and innovation.

Market Dynamics: Increasing awareness regarding nasopharyngeal cancer drive market growth

There is a rising awareness of the diagnosis and treatment of nasopharyngeal cancer. Conventionally, the public perception concerning nasopharyngeal cancer was low due to the lack of government initiatives and the relatively low incidence rate of the disease. To boost community awareness for ethnicities prone to nasopharyngeal cancer, several primary healthcare centers have begun awareness campaigns to enhance the awareness of nasopharyngeal cancer. Therefore, greater adoption of nasopharyngeal cancer diagnosis and treatment is being witnessed, driving the growth of the global nasopharyngeal cancer market.

However, the High treatment cost of nasopharyngeal cancer negatively impacted the market growth. The high price of therapeutic procedures, such as chemotherapy, surgeries, and radiation therapy, results in out-of-pocket expenditure among non-insured cancer patients. The high price of drugs adds to the overarching financial burden of the treatment. It can act as a barrier to the global nasopharyngeal cancer treatment market. With so many advantages of the nasopharyngeal cancer market, it has a few disadvantages too. The high cost of the treatment and side effects are a barrier to the nasopharyngeal cancer market.

Market Segmentation: The cryosurgery devices segment will project the fastest growth in the market throughout the forecast period

Based on therapy, the nasopharyngeal cancer market has been classified into chemotherapy, immunotherapy, radiation therapy and others

Radiation Therapy is expected to hold a significant market share in the treatment therapy segment. Radiation therapy forms the main modality of treatment for nasopharyngeal cancer. Newer and advanced solutions for nasopharyngeal cancer treatment include a combination of both chemotherapy and radiotherapy techniques. These treatment modalities are at an early clinical phase and will make a commercial appearance late during the end of the forecast period.

Based on the End User, the animal stem cell therapy market has been classified into hospitals & clinics, ambulatory surgery centers and others

The hospitals & clinics segment is anticipated to hold the largest share in the global market. The rapid adoption of technologies is expected to boost the nasopharyngeal cancer treatment market. This trend is likely seen in emerging regions where healthcare expenditure is increasing considerably. Developed regions are observing that since the availability of nasopharyngeal cancer treatment and procedure is easily available, the demand for the nasopharyngeal cancer market has increased. Companies are investing heavily in emerging regions to offer efficient treatment solutions for higher healthcare quality, greater efficiency and better patient outcomes.

Geographical Penetration: Asia Pacific is the dominating region during the forecast period.

Based on geography, the study analyzes the animal stem cell therapy market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

The Asia Pacific is expected to witness the fastest growth during the forecast period. In the Asia Pacific, nasopharyngeal cancer is one of the most widespread cancers in the head and neck areas. Men are two to three times more likely to grow it than women. The peak age of prevalence is between 50 and 60 years. This cancer is generally more common in Southeast Asia. Moreover, the five countries with the greatest incidence of nasopharyngeal cancer worldwide were Indonesia, China, Vietnam, India and Malaysia, respectively. According to the research published by the American Cancer Society, in some parts of China, there are as many as 25 to 30 cases per 100,000 men and 15 to 20 cases per 100,000 women. Developed regions are witnessing that since accessibility for nasopharyngeal cancer treatment and procedures are easily accessible and available, the demand for the nasopharyngeal cancer market has increased. Companies are investing heavily in developing regions to offer effective treatment solutions for higher care quality, greater efficiency and better patient outcomes. Moreover, increasing healthcare awareness, along with increasing spending on IT and healthcare technologies in developing regions, is expected to boost the overall demand for effective treatment in the nasopharyngeal cancer market.

Competitive Landscape:

The nasopharyngeal cancer market is highly competitive, owing to the presence of big competitive players in the market. Some major key players in the market are Bristol-Myers Squibb, Cyclacel Pharmaceuticals Inc., Eli Lilly And Co., GLAXOSMITHKLINE PLC, Merck & Co., Inc., Novartis International AG, ONO PHARMACEUTICAL CO. Safoni, Theravectys SA, among others. The major players are adopting new product launches and expansion strategies for global growth in the nasopharyngeal cancer market. In March 2022, Bristal Mayer Squibb acquired Turning Point Therapeutics, a Leading Precision Oncology Company, for $76.00 per Share. This acquisition helps to expand companies leading oncology franchise by adding a best-in-class, late-stage precision oncology asset. In July 2021, Eli Lilly announced the acquisition of promoter technologies, a private biotech company, to advance treatment for type 1 diabetes (TD1) for $1bn. This acquisition accelerates next-generation life-changing therapies for people living with T1D. In April 2021, GLAXOSMITHKLINE PLC, a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, acquired Sierra Oncology; a California based Biopharmaceutical Company focused on targeted therapies for the treatment of rare disease Cancer, for USD 1.9 Billion. This acquisition includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address the critical unmet medical needs of myelofibrosis patients with anemia. This acquisition helps to expand the innovative oncology portfolio.

COVID-19 Impact: Negative impact on the global nasopharyngeal cancer market.

The COVID-19 pandemic has hampered the growth of the nasopharyngeal cancer market, owing to the decline in hospital visits and the diagnosis rate of the disease amidst the pandemic. Cancer patients are predominantly elderly and immunosuppressed, and clinical data shows that they may be more susceptible to COVID-19 infection. The major concern during the COVID-19 pandemic was to stay safe at home and boost immunity, which has declined clinic visits, leading to the downfall in the nasopharyngeal cancer market in 2020.

The global nasopharyngeal cancer market report would provide an access to approximately 50 market data tables, 42 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Therapy
3.2. Market Snippet by End User
3.3. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing awareness regarding nasopharyngeal cancer
  - 4.1.1.2. Advancement in technology
- 4.1.2. Restraints:
  - 4.1.2.1. High treatment cost of nasopharyngeal cancer
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Therapy

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Segment
7.3. Market Attractiveness Index, By Therapy Segment
- 7.3.1. Chemotherpy*
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Immunotherapy
- 7.3.3. Radiation therapy
- 7.3.4. Others

8. By End User

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
8.3. Market Attractiveness Index, By End User Segment
- 8.3.1. Hospitals & Clinics*
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Ambulatory surgery centers Electronic
- 8.3.3. Others

9. By Region

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. U.S.
  - 9.4.5.2. Canada
  - 9.4.5.3. Mexico
9.5. Europe
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. Germany
  - 9.5.5.2. U.K.
  - 9.5.5.3. France
  - 9.5.5.4. Italy
  - 9.5.5.5. Spain
  - 9.5.5.6. Rest of Europe
9.6. South America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.6.5.1. Brazil
  - 9.6.5.2. Argentina
  - 9.6.5.3. Rest of South America
9.7. Asia Pacific
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.7.5.1. China
  - 9.7.5.2. India
  - 9.7.5.3. Japan
  - 9.7.5.4. Australia
  - 9.7.5.5. Rest of Asia Pacific
9.8. Middle East and Africa
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Nasopharyngeal Cancer Market- Company Profiles

11.1. Bristol-Myers Squibb Co.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Biodiem Ltd.
11.3. Cyclacel Pharmaceuticals Inc.
11.4. Eli Lilly And Co.
11.5. GlaxoSmithKline Plc.
11.6. Merck & Co., Inc.
11.7. Novartis International AG
11.8. Ono Pharmaceutical Co.,
11.9. SafoniTheravectys SA (List Not Exhaustive)